DCC-3116_product_DataBase

Bioactivity	DCC-3116 is an orally active ULK1/2 inhibitor. DCC-3116 can promote autophagy in lung cancer cells by inhibiting KRASG12C signaling, thereby inhibiting the proliferation of lung cancer cells and exerting anti-cancer effects[1].
Invitro	DCC-3116 (100 nM, 72 h) 单独使用可抑制 NCI-H2122 和 Calu-1 细胞增殖，减少 pS318-ATG13 表达，与 Sotorasib (HY-114277) 联合使用时具有协同作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> DCC-3116 相关抗体:
In Vivo	DCC-3116 (每天服用 3 or 30 mg/kg，连续使用 56 天， p.o. and p.i.) 单独使用或与 Sotorasib (HY-114277) 联合使用都可以抑制 NSCLC 肺癌小鼠模型的肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	2543673-19-2
Formula	C26H36F3N7O2
Molar Mass	535.60
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Ghazi PC, et al. Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer. bioRxiv [Preprint]. 2024 Feb 8:2024.02.06.579200.

PeptideDB